BC 064 – Sémaglutide dans l’insuffisance rénale chronique et le diabète type 2 (étude FLOW)

Dans cette 64e baladodiffusion, le Dr Luc Lanthier discute de l’utilisation du sémaglutide comme thérapie néphroprotectrice dans l’insuffisance rénale chronique chez les personnes avec diabète type 2, en plus de réviser la littérature médicale de juin 2024.   Quiz clinique (1 min 55), présentation principale (2 min 40), critique (25 min 22), retour sur le cas clinique (35 min 04), autres articles (37 min 10), réponse au quiz clinique (40 min 17)   Référence principale :   Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. PubMed PMID: 38785209.   Articles associés :    Herrington WG, Haynes R. Diabetic Kidney Disease – Semaglutide Flows into the Mainstream. N Engl J Med. 2024;391(2):178-179. PubMed PMID: 38986062.   Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024 Jun 24. doi: 10.1038/s41591-024-03133-0. PubMed PMID: 38914124.   https://kidneyfailurerisk.com   https://www.ontariorenalnetwork.ca/en/kidney-care-resources/clinical-tools/primary-care-tools/kidneywise/toolkit   Autres articles d’intérêt récent :    Aaron SD, Vandemheen KL, Whitmore GA, Bergeron C, Boulet LP, Cote A, et al. Early Diagnosis and Treatment of COPD and Asthma – A Randomized, Controlled Trial. N Engl J Med. 2024;390(22):2061-73. PubMed PMID: 38767248.   Li S, Gu HQ, Li H, Wang X, Jin A, Guo S, et al. Reteplase versus Alteplase for Acute Ischemic Stroke. N Engl J Med. 2024;390(24):2264-73. PubMed PMID: 38884332. Gibbs KW, Semler MW, Driver BE, Seitz KP, Stempek SB, Taylor C, et al. Noninvasive Ventilation for Preoxygenation during Emergency Intubation. N Engl J Med. 2024;390(23):2165-77. PubMed PMID: 38869091.   Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024;390(24):2274-83. PubMed PMID: 38767614.   McCormick N, Yokose C, Lu N, Wexler DJ, Avina-Zubieta JA, De Vera MA, et al. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin. JAMA Intern Med. 2024;184(6):650-60. PubMed PMID: 38619822.   Guides de pratique :    Pacheco C, Coutinho T, Bastiany A, Beanlands R, Boczar KE, Gulati M, et al. Canadian Cardiovascular Society/Canadian Women’s Heart Health Alliance Clinical Practice Update on Myocardial Infarction With No Obstructive Coronary Artery Disease (MINOCA). Can J Cardiol. 2024;40(6):953-68. PubMed PMID: 38852985.   Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e311. PubMed PMID: 38718139.   Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(24):e1313-e410. PubMed PMID: 38743805.   Références du quiz clinique :   Merz LE, Story CM, Osei MA, Jolley K, Ren S, Park HS, Yefidoff Freedman R, Neuberg D, Smeland-Wagman R, Kaufman RM, Achebe MO. Absolute neutrophil count by Duffy status among healthy Black and African American adults. Blood Adv. 2023;7(3):317-320. PubMed PMID: 35994632.   https://www.ncbi.nlm.nih.gov/books/NBK2271/